An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Therapeutic Use
- Sponsors Cell Biopeutics Resources
Most Recent Events
- 06 Feb 2024 Status changed from not yet recruiting to recruiting.
- 17 May 2023 New trial record